<DOC>
	<DOCNO>NCT00002265</DOCNO>
	<brief_summary>To demonstrate zalcitabine ( dideoxycytidine ; ddC ) monotherapy safe tolerable treatment patient AIDS advance AIDS relate complex ( ARC ) previously demonstrate intolerance zidovudine ( AZT ) treatment Protocol N3300 ( NIAID ACTG 114 ) N3492 ( NIAID ACTG 119 ) . NOTE OF CAUTION FOR CONCOMITANT MEDICATIONS ON STUDY : Patients amphotericin , pyrimethamine , sulfadiazine , trimethoprim/sulfamethoxazole , ganciclovir , intravenous pentamidine , intravenous acyclovir oral acyclovir bone marrow renal toxic drug may tolerate concomitant ddC . If drug give concomitantly ddC , patient frequent clinical laboratory assessment , appropriate . Drugs nephrotoxic potential cause peripheral neuropathy might expect cause increase toxicity co-administered ddC . Drugs could cause serious additive toxicity co-administered study medication allow treatment acute intercurrent illness opportunistic infection discretion investigator . Their use may allow interruption study drug 35 day per episode , total 90 day study . If patient 's condition require chronic administration medication , patient discontinue study medication follow .</brief_summary>
	<brief_title>An Open-Label , Multicenter Study Evaluate Safety Tolerability Dideoxycytidine ( ddC ) Patients With AIDS Advanced ARC Who Previously Demonstrated Intolerance Zidovudine ( AZT ) Protocol N3300 N3492</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zalcitabine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Recommended : Prophylactic aerosolized pentamidine . Allowed maintenance recover infection initially prescribe : Pyrimethamine . Sulfadiazine . Amphotericin . Fluconazole . Ketoconazole ( = &lt; 400 mg/day ) . Acyclovir ( = &lt; 1000 mg/day ) . Ganciclovir . Medications tuberculosis Mycobacterium avium infection . Allowed : Erythropoietin . Megace . Trimethoprim/sulfamethoxazole &lt; = 20 mg/kg/day . Nystatin . Low dose acetaminophen nonsteroidal antiinflammatory agent ( = &lt; 3 g/day ) . Medications patient stable 14 day prior study entry . Allowed evidence peripheral neuropathy study entry : Isoniazid ( must receive pyridoxine = &gt; 50 mg/day concomitantly ) . Phenytoin , stable = &gt; 3 month . Metronidazole study medication interruption pre post test peripheral neuropathy . Any sign patient restart study medication . REFER TO NOTE OF CAUTION IN PROTOCOL SUMMARY . Patients must follow : Previously enrol NIAID ACTG 114 NIAID ACTG 119 . Experienced = &gt; grade 3 zidovudine ( AZT ) relate toxicity enrol assign protocol follow procedure study drug dose reduction , interruption , rechallenge permanent discontinuation per NIAID ACTG 114 NIAID ACTG 119 . NOTE : After permanent study drug discontinuation NIAID ACTG 114 drug code may break ONLY discussion HoffmannLa Roche regard toxicity management probable relationship AZT . Although NIAID ACTG 119 openlabel study , investigator also contact HoffmannLa Roche prior enter patient protocol . Toxicities must `` probably '' AZT relate ( determine investigator follow discussion sponsor ) patient eligible inclusion protocol . Toxicities must resolve = &lt; grade 2 within 45 day discontinuation AZT NIAID ACTG 114 NIAID ACTG 119 . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : An active AIDS defining opportunistic infection active intercurrent illness ongoing treatment require use excluded medication ( see Exclusion Concurrent Medications ) . Baseline fever &gt; 38.5 C cause occult opportunistic infection neoplasm require continuous treatment exclude medication . If evaluation infection unrevealing , patient may enter evaluation complete mycobacterial culture still pending . Patients history unexplained fever &gt; 38.5 C evaluate and/or afebrile ( T &lt; 38.0 C ) 2 week prior study entry . Severe AIDS dementia complex define score &lt; 23 MiniMental State Exam time discontinuation NIAID ACTG 114 NIAID ACTG 119 . Any history peripheral neuropathy moderate severe peripheral neuropathy define : A score = &gt; 4 one category score = &gt; 2 two category peripheral neuropathy segment Signs Symptoms Questionnaire . Accompanied : Results Standardized Neurological exam indicative moderate abnormality , particularly impaired sensation sharp pain , light touch vibration low extremity , distal extremity weakness distal extremity hyporeflexia . Significant cardiac disease , define history ventricular arrhythmia require medication , prior myocardial infarct history angina ischemia change EKG . Significant liver disease , define transaminase &gt; 5 x upper limit normal history cirrhosis ascites . Significant renal disease define estimate creatinine clearance &lt; 50 ml/min . Concurrent Medication : Excluded : Other antiretroviral agent . Biologic modifier . Corticosteroids . Other experimental agent include : Foscarnet . Ribavirin . ddI . Drugs could cause peripheral neuropathy include : Hydralazine . Nitrofurantoin . Vincristine . Cisplatin . Dapsone . Disulfiram . Diethyldithiocarbamate . Patients follow exclude : An active AIDS defining opportunistic infection active intercurrent illness ongoing treatment require use excluded medication ( see Exclusion Concurrent Medications ) . Such patient allow study complete therapy exclude concomitant medication stable 14 day . Had discontinue study medication NIAID ACTG 114 NIAID ACTG 119 opportunistic infection intercurrent illness require continuous treatment medication allow concomitant administration NIAID ACTG 114 ACTG 119 . Symptoms condition define patient Exclusion CoExisting Condition . Active substance alcohol abuse . Unwillingness deem unable sign inform consent . Prior Treatment : Excluded within 30 day study entry : Radiation therapy . Active substance alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 1994</verification_date>
	<keyword>Zalcitabine</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Zidovudine</keyword>
</DOC>